RPE65 and Retinal atrophy: Retinal atrophy has also been described after treatment with voretigene neparvovec for RPE65-RD yet was not preceded by hyperpigmentation and developed progressively within 3 months post-treatment, suggesting a different causal mechanism than that observed in our trial28–30.